News
Recruitment open to Spevigo (spesolimab)
We are now accepting patients on Spevigo (spesolimab). Spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (GPP). BADBIR can accept registrations for patients with a GPP diagnosis.Please see the eligibility page for...
Recruitment re-open to Stelara, Humira, Amgevita, Hulio, Hyrimoz, Idacio, Yuflyma
BADBIR is now open to registrations of patients commencing on the following drugs: Stelara (ustekinumab), Humira (adalimumab), Amgevita (adalimumab), Hulio (adalimumab), Hyrimoz (adalimumab), Idacio (adalimumab) and Yuflyma (adalimumab).
A sprinkle of methotrexate to go with biologics: a safe recipe?
Oras A Alabas, Zenas Z N Yiu British Journal of Dermatology, Volume 190, Issue 3, March 2024, Pages 302–303 https://doi.org/10.1093/bjd/ljad505 Related Contact Us Tel: +44 (0)161 306 1896 Email: badbir@manchester.ac.uk Find Us The...
Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis
JAMA Dermatology, 2023.Ali Al-Janabi; Oras A. Alabas; Zenas Z. N. Yiu; Amy C. Foulkes; Steve Eyre; Adnan R. Khan; Nick J. Reynolds; Catherine H. Smith; Christopher E. M. Griffiths; Richard B. Warren; the BADBIR Study Group.Read publication: JAMA Dermatology Related...
The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
BJD, 2023.Oras A. Alabas, Kayleigh J. Mason, Zenas Z.N. Yiu, Richard B. Warren, Nick Dand, Jonathan N.W.N. Barker, Catherine H. Smith, Christopher E.M. Grifï¬ths, the BADBIR and BSTOP study group.Read publication: BJD Related Contact Us...
Characteristics of “super responders” and “super nonresponders” to first biologic monotherapy for psoriasis: a nested case-control study
BJD, 2023.Kayleigh J. Mason, Oras A. Alabas, Nick Dand, Richard B. Warren, Nick J. Reynolds, Jonathan N.W.N. Barker, Zenas Z. N. Yiu, Catherine H. Smith, Christopher E.M. Griffiths, the BADBIR Study Group.Read publication: BJD Related ...
Password policy updates to the BADBIR Database
In our ongoing commitment to maintaining a secure and user-friendly online environment, we are updating our password policy. We kindly request all our users to consider reviewing and enhancing the strength of their passwords in preparation for the new criteria, which...
Centre of the month: October 2023
Imperial College Healthcare NHS Trust was selected for their hard work keeping on top of outstanding follow-ups. A message from Imperial College: We treat our patients as customers. We do not stop after they are recruited to the study or attending follow up. We...
Atopic Polygenic Risk Score Is Associated with Paradoxical Eczema Developing in Patients with Psoriasis Treated with Biologics
JID, 2023.Al-Janabi A, Eyre S, Foulkes AC, Khan AR, Dand N, Burova E, DeSilva B, Makrygeorgou, Davies E, Smith CH, Griffiths CEM, Morris AP, Warren RB; BSTOP & BADBIR Study Groups.Read publication: JID Related Contact Us Tel: +44 (0)161...
Recruitment to Kyntheum, Cimzia and Skilarence ending; Sotyktu registrations now accepted
Recruitment to Kyntheum (brodalumab), Cimzia (certolizumab pegol), and Skilarence (dimethyl fumarate) has now ended. Patients who were consented and started these treatments before the 1st August must be added to the database before 21st August. Recruitment is...
Contact Us
Find Us
The University of Manchester
First Floor Bright Building
Manchester Science Park
Manchester
M15 6GZ
